BridgeBio Pharma announced it will present primary results from its Phase 3 CALIBRATE trial of encaleret, a treatment for autosomal dominant hypocalcemia type 1 (ADH1), at the 2026 European Congress of Endocrinology in Prague. The company will share multiple presentations including oral talks and posters detailing the trial outcomes and genetic findings related to ADH1. This data is significant as it highlights potential advancements in treating a rare genetic condition with limited options. The presentations are scheduled for May 9-12, 2026, providing insights into encaleret's effectiveness and the genetic basis of ADH1.
BridgeBio Pharma announced that acoramidis, a drug for transthyretin amyloid cardiomyopathy (ATTR-CM), demonstrated early and sustained kidney-protective effects in clinical trials. The drug caused a reversible dip in kidney filtration rate and reduc...
BridgeBio Pharma secured $1 billion through preferred equity investment led by Sixth Street and HealthCare Royalty to support upcoming drug launches and strengthen its financial position. The funding comes as BridgeBio prepares to launch three potent...
BridgeBio Pharma is rated a Buy due to the commercial launch of Attruby and its promising late-stage pipeline focused on rare genetic diseases. The company's valuation exceeds $14 billion, supported by four potential blockbuster drugs expected by 203...
BridgeBio Pharma announced that the Phase 3 PROPEL 3 trial of oral infigratinib in children with achondroplasia demonstrated significant improvements in height velocity, body proportionality, and arm span compared to placebo. These results, published...
